- Home
- CYH vs ALLO Comparison
CYH vs ALLO Comparison
Compare CYH & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- ALLO
- Stock Information
- Founded
- CYH 1985
- ALLO 2017
- Country
- CYH United States
- ALLO United States
- Employees
- CYH N/A
- ALLO N/A
- Industry
- CYH Hospital/Nursing Management
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYH Health Care
- ALLO Health Care
- Exchange
- CYH Nasdaq
- ALLO Nasdaq
- Market Cap
- CYH 362.0M
- ALLO 338.9M
- IPO Year
- CYH 1991
- ALLO 2018
- Fundamental
- Price
- CYH $3.51
- ALLO $1.21
- Analyst Decision
- CYH Hold
- ALLO Strong Buy
- Analyst Count
- CYH 8
- ALLO 10
- Target Price
- CYH $4.02
- ALLO $9.66
- AVG Volume (30 Days)
- CYH 3.4M
- ALLO 2.9M
- Earning Date
- CYH 04-23-2025
- ALLO 05-13-2025
- Dividend Yield
- CYH N/A
- ALLO N/A
- EPS Growth
- CYH N/A
- ALLO N/A
- EPS
- CYH N/A
- ALLO N/A
- Revenue
- CYH $12,653,000,000.00
- ALLO $22,000.00
- Revenue This Year
- CYH N/A
- ALLO N/A
- Revenue Next Year
- CYH $4.15
- ALLO $9.07
- P/E Ratio
- CYH N/A
- ALLO N/A
- Revenue Growth
- CYH 1.05
- ALLO N/A
- 52 Week Low
- CYH $2.24
- ALLO $1.09
- 52 Week High
- CYH $6.29
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- CYH 72.58
- ALLO 38.89
- Support Level
- CYH $2.77
- ALLO $1.09
- Resistance Level
- CYH $3.50
- ALLO $1.78
- Average True Range (ATR)
- CYH 0.20
- ALLO 0.14
- MACD
- CYH 0.10
- ALLO -0.03
- Stochastic Oscillator
- CYH 90.09
- ALLO 27.46
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.